the heel is common and occasionally is responsible for their initial symptom to seek clinics. An early or timely recognition of active enthesitis of AS from simple radiographs comes to be relevant issue.

Objectives: The purpose of current study is to assess measurement reliability and diagnostic validity for detecting the digital radiographic findings of enthesitis at the Achilles tendon insertion in patients with AS.

Methods: Current study is a blinded, matched, cross-sectional study with 44 patients (65 feet) having clinical enthesitis at the Achilles tendon insertion (Group I), and 44 healthy controls (65 feet) (Group II). Suggested findings of enthesitis including retrocalcaneal recess obliterations from retrocalcaneal bursitis, increased thickness in shadow of the Achilles tendon and posterior soft tissue at its insertion from the swellings of those soft tissues were assessed on digital radiographs of standing hindfoot lateral view, and their measurement reliabilities were determined. To investigate diagnostic validities, diagnostic odds ratio, sensitivity, specificity, positive likelihood ratio (PLR), and negative likelihood ratio (NLR) were estimated for radiographic findings of retrocalcaneal recess obliterations (RRO). For the thickness of the Achilles at its insertion (TAI) and swollen posterior soft tissue, the receiver operating characteristic (ROC) curve analysis was done.

Results: There were no significant differences between two groups in mean age, BMI and sex ratio. Intra- and inter-observer reliability of all measurements showed high degree of agreements (0.786 to 0.941). The diagnostic odds ratio of RRO for detecting enthesitis was 66.0. The sensitivity, specificity were 67.7%, 96.9%, and PLR, NLR were 22.0, 0.33, respectively. The mean TAI of Group I and II were 6.7mm±1.79, 5.01mm±0.81, respectively (p-value<0.001). Area under the ROC curve of the TAI was 0.806, and the optimal cut-off value predicting enthesitis was 5.47mm, and its sensitivity and specificity were both 72.3%.

Conclusions: Retrocalcaneal recess obliteration and thickened shadow of Achilles tendon at its insertion and swollen posterior soft tissue on digital radiographs of standing hindfoot lateral view are regarded as the easy and useful findings for enthesitis of the posterior heel. For searching enthesitis at the Achilles insertion in patients with AS, such findings from simple radiographs showed high measurement reliability and validity.

References:

- [1] Resnick D, Feingold ML, Curd J, Niwayama G, Goergen TG. Calcaneal abnormalities in articular disorders. Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and Reiter syndrome. *Radiology* 1977;125:355–66.
- [2] Freedman M, Steller D. Digital radiography of the musculoskeletal system: the optimal image. *Journal of digital imaging* 1995;8:37–42.
- [3] Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? *Arthritis and rheumatism* 2005;52(4):1000–1008.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.4565

FRI0443 THE EFFECT OF FIBROMYALGIA ON DISEASE ACTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS

I. Shapoval, M. Stanislavchuk, K. Zaichko, L. Perebetyuk. *Internal Medicine, National Pirogov Memorial Medical University, Vinnytsya, Ukraine*

Background: Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that affects the axial skeleton and characterized by pain, stiffness and fatigue [4]. One of the frequent concomitant condition in patients with AS is fibromyalgia (FM). FM shares some common symptoms with AS. According to the many reports concomitant FM in patients with AS has been found in 5.7 - 41.3% cases [1, 2, 3, 5]. Due to the fact that pain is a major component of the disease activity scores of the AS (Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS)), concomitant FM can significantly modify the disease activity in patients with AS.

Objectives: The aim of this study was to evaluate the effect of FM on disease activity in patients with AS.

Methods: Diagnosis of AS was identified according to the modified New York criteria (1984). FM was diagnosed by ACR criteria (1990). Disease activity was assessed by BASDAI and ASDAS.

Results: 80 patients with AS were included into study (15 females and 65 males), age (M ± SD) 41.64±11.4 years. Nineteen patients (23.8%) met the criteria for FM. Patients with AS and AS+FM were representative for age and disease duration. In both groups, ESR (37.7±18.8 and 39.00±19.6 mm/h) was comparable, while ASDAS and BASDAI were significantly different. The disease activity according to both scores was higher in patients with AS+FM. According to the BASDAI in patients with AS disease activity was 5.20±1.4 whereas in patients with AS and FM - 7.14±1.7; according to the ASDAS-ESR difference in disease activity was slightly lower, but remained significant (3.6±0.8 vs 4.2±0.9).

Conclusions: The obtained data indicates that concomitant FM is a frequent condition in patients with AS. Presence of FM in patients with AS significantly modifies the disease activity determined by ASDAS. The ASDAS-ESR is more appropriate for determining the disease activity comparing to BASDAI, because included in calculation ESR diminish the distorting effect of FM.

References:

- [1] Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity/Fausto Salaffi, Rossella De Angelis, Marina Carottiet al. *Rheumatology International* 2014;1103–1110.

- [2] Occurrence of fibromyalgia in patients with ankylosing spondylitis. /ValderilioFeijó Azevedo, Eduardo dos Santos Paiva, Lúcio Ricardo HwurkoFelipe, Ranieri Amorim Moreira. *Bras J Rheumatol* 2010;50:646–654.

- [3] Ankylosing spondylitis functional and activity indices in clinical practice. Popescu C, Trandafir M, Bădică AM et al. *Journal of Medicine and Life* 2014;78–83.

- [4] Global prevalence of ankylosing spondylitis. Linda E. Dean, Gareth T. Jones, Alan G. MacDonald et al. *Rheumatology* 2014;53:650–657.

- [5] Prevalence of fibromyalgia in patients with ankylosing spondylitis Medical Journal of Dr. D.Y. Patil University 2014:338–341.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.3967

FRI0444 INCIDENCE OF INFLAMMATORY BOWEL DISEASE EVENTS IN ADALIMUMAB CLINICAL TRIALS ACROSS INDICATIONS

J.R. Curtis¹, D. Elewaut², S. Chen³, M. Hohnik⁴, N. Naveh⁵, J.K. Anderson³.

¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, United States; ²VIB Inflammation Research Center, University of Gent, Gent, Belgium; ³AbbVie Inc., North Chicago, United States;

⁴AbbVie, Ljubljana, Slovenia; ⁵AbbVie, Hod HaSharon, Israel

Background: Adalimumab (ADA) is approved for treatment of Crohn's disease (CD) and ulcerative colitis (UC); therefore, it is postulated that new onset or flare of inflammatory bowel disease (IBD) is a rare occurrence in ADA clinical trials for non-IBD indications.

Objectives: The purpose of this analysis was to determine the rates of IBD adverse events (AEs) in ADA clinical trials, particularly in spondyloarthritis (SpA) patients (pts) who are at higher risk of IBD as a feature of SpA.

Methods: The rates of IBD AEs in 73 phase 2–4 interventional ADA clinical trials in rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (pJIA), pediatric enthesitis-related arthritis, uveitis (non-infectious intermediate, posterior, or pan-uveitis), hidradenitis suppurativa (HS), adult and pediatric psoriasis (Ps), psoriatic arthritis (PsA), non-PsA peripheral SpA (pSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) were analyzed (trials in UC, CD, and intestinal Behcet's disease [BD] were excluded). The search criteria for IBD events included the following standardized MedDRA queries preferred terms: inflammatory bowel disease (IBD), ulcerative colitis (UC), Crohn's disease (CD), IBD-not otherwise specified (NOS), and ulcerative proctitis. The incidence rates (IR) for events of IBD (combined new onset and flare) in interventional clinical trials of ADA are reported as events per 100 pt-years (PY). 95% confidence intervals (CI) were based on exact Poisson confidence limits.

Results: ADA was administered to 23735 pts, representing 36404.6 PY of exposure. Overall, the IR for IBD events in all interventional ADA trials included in this analysis was 0.1/100PY (Table). The rates of IBD events varied across therapeutic indications from <0.1 to 0.8/100PY. There were no reports of IBD events in pediatric pts. The IR for IBD events in RA, uveitis, HS, and Ps trials were <0.1, 0.2, 0.4, and <0.1/100 PY. In SpA, the overall rates of IBD were 0.5/100 PY, while the rates were 0, 0.8, 0.5, and 0.7/100 PY in PsA, non-PsA pSpA, nr-axSpA, and AS, respectively. 2216 pts with axSpA (AS: 2026, nr-axSpA: 190) were exposed to ADA; in AS, 14 IBD events (7 new onset and 7 flares) were reported in 12 pts (7 new onset and 5 flares), while in nr-axSpA, 2 IBD events were reported in 1 pt (2 flares).

Table. Incidence of IBD events in patients from ADA clinical trials.

Indication	N (PYs)	All IBD AEs, n [§]	IR/100 PY (95% CI)
All ADA trials [†]	23735 (36404.6)	40	0.1 (0.1 – 0.2)
Rheumatoid Arthritis	15152 (24813.0)	16	<0.1 (0.0 – 0.1)
Uveitis	387 (538.8)	1	0.2 (0.0 – 1.0)
Hidradenitis suppurativa	733 (836.3)	3	0.4 (0.1 – 1.1)
Psoriasis	3500 (5268.7)	1	<0.1 (0.0 – 0.1)
All SpA [‡]	3218 (3919.9)	19	0.5 (0.3 – 0.8)
PsA	837 (997.5)	0	0.0 (0.0 – 0.4)
Non-PsA pSpA	165 (390.7)	3	0.8 (0.2 – 2.2)
All axSpA [‡]	2216 (2531.7)	16	0.6 (0.4 – 1.0)
nr-axSpA	190 (412.2)	2	0.5 (0.1 – 1.8)
AS	2026 (2119.5)	14	0.7 (0.4 – 1.1)

[§]No IBD events were reported in pediatric patients.

[†]All ADA adult and pediatric patients in all interventional studies excluding Crohn's disease, ulcerative colitis, and intestinal Behcet's disease.

[‡]All ADA patients in all interventional studies of PsA, non-PsA pSpA, nr-axSpA, and AS.

[§]All ADA patients in all interventional studies of nr-axSpA and AS. Abbreviations: IBD = inflammatory bowel disease; ADA = adalimumab; PY = patient years; AEs = adverse events; IR = incidence rates; CI = confidence interval; SpA = spondyloarthritis; PsA = psoriatic arthritis; pSpA = non-PsA peripheral spondyloarthritis; axSpA = axial spondyloarthritis; nr-axSpA = non-radiographic axSpA; AS = ankylosing spondylitis.

Conclusions: The rates of IBD AEs in ADA clinical trials were generally low across all indications, with all events occurring in adult pts. In AS pts, who are at increased risk of manifesting IBD, the rates of IBD for pts treated with ADA (0.7/100 PY [95% CI, 0.4–1.1]) were similar to published placebo rates pooled